| Management |
| Jean-Patrick Voisin, MBA C.E.O. |
| Luc Lenglet, ENS C.E.O. Magnisense France |
| Petr Nikitin, PhD Chief Scientific Officer |
| Senior Advisory Board |
| Dominique Bellet, PharmD, MD, PhD |
| Jean-Claude Mongrenier, PharmD, MBA |
| Christian Policard, Docteur in Biochemistry |
| Partners |
| Russian Academy of Sciences |
| University of Paris 13 |
University of Paris 13
The Paris 13 University is the largest multi-discipline university in France, teaching biology, medicine, chemistry, physics, mathematics, and gathering nearly 22000 students. The Bionanomaterials activity (CSPBAT laboratory CNRS 3043, C2B team) directed by Pr. Laurence Motte has built a nanoplatform, dedicated to the elaboration and characterization of magnetic nanobiovectors, for molecules vectorization, diagnostic and therapeutic applications, closely with the Avicenne hospital. |
Our History
May 2003: Magnisense created by Baring Vostok Capital Partners and private investors.
2003 – 2006: Technical development carried out jointly by Petr Nikitin’s team in Moscow and Bertin Technologies in France for engineering.
June 2006: Second round of financing.
November 2006: Business development teams created both in Europe and in the USA.
September 2007: New patent application filed for a multiparametric magnetic immunoassay, MIAplex™.
February 2008: Creation of Magnisense Biological Development Laboratory in Dardilly, France.
December 2008: Third round of financing.
2008 – 2009: Several external validation studies on-going with leading human and veterinary IVD players.